Mark McDade

Mark is a managing partner of the Qiming U.S. Healthcare Fund. Previously, he served as chief operating officer of UCB Pharma, CEO of PDL BioPharma, CEO of Signature BioScience and COO of Boehringer Mannheim Therapeutics. He serves on the boards of FivePrime Therapeutics, Dermira Inc., and Aimmune Therapeutics. He received his M.B.A. from Harvard Business School.